Canadian psychedelics firm Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) is receiving new federal licensing that the firm says will allow it to expand research on psilocybin.
On Monday, the company says the Containment Level 2 licence will support testing for the study and sale of natural products.
Numinus received the licensing for its Bioscience lab after upgrading the facility. According to a statement, the addition will contribute new data on natural psychedelics, with intellectual property opportunities as well as drive revenue through contracted research services.
With the licence, the firm says it will study pathogens and contaminants to identify optimal growth conditions for psilocybe mushrooms; conduct bioassay studies using mammalian cell lines to analyze the bioactivity of different psychedelic compounds; and start pre-clinical studies using body fluids to investigate reactions in the human body to whole mushrooms and other natural formulations.
Read more: Numinus uplists to OTCQX Best Market
“This biosecurity expansion will allow us to deeply understand not only the mechanisms behind psilocybe mushrooms and other naturally occurring psychedelic materials but also their interaction with the human body,” science officer and general manager Sharan Sidhu said in the statement.
“By performing testing and validation at a highly precise level, we will advance both our own IP development of finished products and scaled production processes, as well as contract services and sale of materials to research and industry partners.”
CEO Payton Nyquvest says the authorization moves his company closer to developing medicines at scale to support psychedelic-assisted therapy.
Numinus also has a dealer’s licence from Health Canada, which allows it to produce and conduct research on certain psychedelic substances.
Last week, the firm received approval to study the DMT-containing brew ayahuasca, and the cactus San Pedro, which contains mescaline.